` MVP (Medical Developments International Ltd) vs S&P/ASX 300 Comparison - Alpha Spread

MVP
vs
S&P/ASX 300

Over the past 12 months, MVP has significantly outperformed S&P/ASX 300, delivering a return of 49% compared to the S&P/ASX 300's 7% growth.

Stocks Performance
MVP vs S&P/ASX 300

Loading
MVP
S&P/ASX 300
Add Stock

Performance Gap
MVP vs S&P/ASX 300

Loading
MVP
S&P/ASX 300
Difference

Performance By Year
MVP vs S&P/ASX 300

Loading
MVP
S&P/ASX 300
Add Stock

Competitors Performance
Medical Developments International Ltd vs Peers

S&P/ASX 300
MVP
LLY
JNJ
NOVO B
ROG
Add Stock

Medical Developments International Ltd
Glance View

Market Cap
64.8m AUD
Industry
Pharmaceuticals

Medical Developments International Ltd. engages in the manufacture and distribution of pharmaceutical drugs, medical, and veterinary equipment. The company is headquartered in Melbourne, Victoria and currently employs 68 full-time employees. The company went IPO on 2003-12-15. The firm is focused on manufacturing and distributing pharmaceutical drugs, and medical and veterinary equipment. The firm operates through three segments: Pharmaceuticals, Medical Devices and Veterinary Products. The Pharmaceuticals segment is engaged in the sale of Penthrox primarily within Australia, New Zealand, Europe and the United Kingdom, and some sales in the Middle East, Asia and South Africa. The Medical Devices segment is engaged in the sale of medical devices, particularly the Space Chamber and Breath-Alert PeakFlow meters, primarily within Australia, the United Kingdom/Europe, North America, and some sales in Asia and New Zealand. The Veterinary Products segment is engaged in the sale of veterinary products within Australia, Europe, and Asia.

MVP Intrinsic Value
0.66 AUD
Undervaluation 13%
Intrinsic Value
Price
Back to Top